Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes.

Lee, You-Bin; Hwang, Hwan-Jin; Kim, Jung A; Hwang, Soon Young; Roh, Eun; Hong, So-hyeon; Choi, Kyung Mook; Baik, Sei Hyun; Yoo, Hye Jin

Objectives: A recent experimental study revealed that family with sequence similarity 19 [chemokine (C-C motif)-like] member A5 (FAM19A5), a novel secreted adipokine, has inhibitory effects on vascular smooth muscle cell proliferation and migration, and on neointima formation in injured arteries. We investigated the associations between serum FAM19A5 concentration and cardio-metabolic risk factors for the first time in human subjects. Methods: Circulating FAM19A5 concentrations and their associations with cardio-metabolic risk factors were explored in 223 individuals (45 without diabetes and 178 with type 2 diabetes). Results: Serum FAM19A5 concentrations (pg/mL) were greater in patients with type 2 diabetes [median (interquartile range), 172.70 (116.19, 286.42)] compared with non-diabetic subjects [92.09 (70.32, 147.24)] (p 2 = 0.0689). Conclusion: A novel adipokine FAM19A5 was related to various metabolic and vascular risk factors in humans, suggesting its potential as a biomarker of cardio-metabolic disease.

Diabetes & Vascular Disease Research, 2019, Vol 16, Issue 6, p530

1479-1641

Academic Journal

10.1177/1479164119860746